Table 1.
Characteristics of the 221 study subjects
| Characteristic | N (Total=221) |
Percent |
|---|---|---|
| Age (in years) at IBEMC enrollment | ||
| < 1 | 100 | 45% |
| 1–2 | 55 | 25% |
| 3–5 | 39 | 18% |
| 6–10 | 24 | 11% |
| Missing | 3 | 1.4% |
| Race | ||
| American Indian or Alaska Native | 0 | 0% |
| Asian | 1 | 0.5% |
| Black or African American | 6 | 2.7% |
| Native Hawaiian or Other Pacific Islander | 0 | 0% |
| White | 189 | 86% |
| Two or More Races | 3 | 1.4% |
| Not Reported or Unknown | 22 | 10% |
| Ethnicity | ||
| Hispanic or Latino | 14 | 6% |
| Not Hispanic or Latino | 191 | 86% |
| Not Reported or Unknown | 16 | 7% |
| Gender | ||
| Male | 117 | 53% |
| Female | 104 | 47% |
| Biochemical diagnostic testing for MCADD | ||
| Any testing | ||
| Done | 202 | 91% |
| Not done | 2 | 1% |
| Plasma acylcarnitine profile | ||
| Done | 166 | 75% |
| Abnormal | 161 | 97% |
| Within normal limits | 4 | 2% |
| Urine organic acids | ||
| Done | 109 | 49% |
| Abnormal | 82 | 75% |
| Within normal limits | 20 | 18% |
| Urine acylglycine profile | ||
| Done | 16 | 7% |
| Abnormal | 15 | 94% |
| Within normal limits | 1 | 6% |
| Enzyme assay | ||
| Done | 0 | 0% |
| Fatty acid oxidation probe assay | ||
| Done | 5 | 2% |
| Abnormal | 5 | 100% |
| Genetic (DNA) testing for MCADD | ||
| Done | 186 | 84% |
| Not done | 21 | 10% |